Show simple item record

dc.contributor.authorVaidya, Neel
dc.date.accessioned2021-09-07T18:47:45Z
dc.date.available2021-09-07T18:47:45Z
dc.date.issued2013-04-20
dc.identifier.urihttp://hdl.handle.net/1951/72144
dc.descriptionBiology & Pharmoeconomics - Panel
dc.description.abstractThis presentation aims at constructing a decision analytic model with the help of TreeAge software package to estimate a cost-effective measure (ICER – Incremental cost effectiveness ratio) for a proposed biosimilar in the US against chemotherapy induced febrile neutropenia for breast cancer patients. This measure of cost-effectiveness will be compared to two currently marketed biologicals, Filgrastim and Pegfilgrastim. A sensitivity analysis along with a probabilistic sensitivity analysis will be performed to test for the robustness of the model. This research aims at estimating whether the biosimilar will be a cost saving drug, as a prophylactic therapy, when it comes into the American market compared to the two current biologicals. With the economic burden of chemotherapy induced neutropenia being quite significant, estimating how the cost-effectiveness equation changes with a new biosimilar in the market is the central theme of this research. The Affordable Care Act of 2010 and the recent presidential elections of 2012 have given a lot of impetus on containing healthcare costs and effective utilization of economic resources. Hence, this form of economic evaluation and decision analysis is a vital segment of research contributing to impacting outcomes research in a big way. Expected Results: Biosimilar Filgrastim is expected to show a superior savings compared to the original Filgrastim biological, while the ICER between the biosimilar and Pegfilgrastim will have to be estimated and published after the model is run. Keywords: biosimilar, cost-effectiveness, febrile neutropenia, ICER, Filgrastim, Pegfilgrastim
dc.language.isoen_US
dc.titleA Cost-Effectiveness Analysis Of A Potential Biosimilar As A Primary Prophylactic Therapy Against Chemotherapy Induced Febrile Neutropenia For Breast Cancer Patients
dc.typepanel
dc.contributor.organizationAlbany College of Pharmacy and Health Sciences
dc.description.institutionSUNY Brockport
dc.description.publicationtitleMaster's Level Graduate Research Conference
dc.source.statuspublished


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record